Immunoprecise Antibodies company info

What does Immunoprecise Antibodies do?
Immunoprecise Antibodies (TSXV:IPA), (NASDAQ:IPA) is a biotechnology firm focused on the discovery and development of innovative antibody-based therapies. The company operates in North America and Europe, leveraging its proprietary platforms to advance the field of monoclonal and bispecific antibodies, along with other recombinant protein-based therapies. Immunoprecise Antibodies aims to address a broad range of diseases, including those in oncology, infectious diseases, and autoimmune disorders. Its projects span from early-stage research to pre-clinical development, with a commitment to delivering high-quality, scalable solutions for its partners and the medical community. Through collaboration and cutting-edge science, the company seeks to make significant contributions to improving human health.
Immunoprecise Antibodies company media
Company Snapshot

Is Immunoprecise Antibodies a public or private company?

key
Ownership
Public

How many people does Immunoprecise Antibodies employ?

people
Employees
102

What sector is Immunoprecise Antibodies in?

pie chart
Sector
Health Care

Where is the head office for Immunoprecise Antibodies?

location pin
Head Office
Victoria, Canada

What year was Immunoprecise Antibodies founded?

founded flag
Year Founded
1983
What does Immunoprecise Antibodies specialise in?
/Antibody Production /Custom Antibodies /Protein Engineering /Monoclonal Antibodies /Pharmaceutical Research /Therapeutic Development

What are the products and/or services of Immunoprecise Antibodies?

Overview of Immunoprecise Antibodies offerings
PolyTope Therapy, a cocktail of monoclonal antibodies designed to treat COVID-19 by targeting multiple viral epitopes, providing a broad-spectrum approach.
TATX-03 PolyTope mAb Therapy, focused on influenza A, aims at preventing and treating various strains simultaneously through a combination of antibodies.
Rapid Prime, a proprietary technology platform for faster, more efficient development of monoclonal and polyclonal antibody therapies against complex targets.
B Cell Select, a customizable antibody discovery platform that isolates high-value B cells for therapeutic development, enhancing specificity and efficacy.
DeepDisplay, a custom phage display library technology enhancing antibody discovery for challenging targets, leveraging vast genetic libraries.
Artemis Intelligence Metadata (AIM), an artificial intelligence-driven platform that streamlines the antibody discovery and development process by predicting outcomes and optimizing selections.

Who is in the executive team of Immunoprecise Antibodies?

Immunoprecise Antibodies leadership team
  • Dr. Jennifer Lynne Bath Ph.D.
    Dr. Jennifer Lynne Bath Ph.D.
    CEO, President & Non-Independent Director
  • Dr. Ilse  Roodink
    Dr. Ilse Roodink
    Chief Scientific Officer & Interim General Manager of IPA Europe, Oss
  • Ms. Kristin  Taylor CPA, M.B.A.
    Ms. Kristin Taylor CPA, M.B.A.
    Chief Financial Officer
  • Mr. David E. Orton
    Mr. David E. Orton
    Chief Operating Officer
  • Dr. Roland  Romijn
    Dr. Roland Romijn
    Head of General Operations of the Utrecht site of IPA (Europe)